Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BIOA 
BioAge Labs, Inc (BIOA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: BIOA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.67
1 Year Target Price $4.67
| 0 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 11.35% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 183.19M USD | Price to earnings Ratio - | 1Y Target Price 4.67 |
Price to earnings Ratio - | 1Y Target Price 4.67 | ||
Volume (30-day avg) 4 | Beta - | 52 Weeks Range 2.88 - 26.62 | Updated Date 10/17/2025 |
52 Weeks Range 2.88 - 26.62 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.81 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1026.99% |
Management Effectiveness
Return on Assets (TTM) -23.46% | Return on Equity (TTM) -35.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -77033782 | Price to Sales(TTM) 47.42 |
Enterprise Value -77033782 | Price to Sales(TTM) 47.42 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 35850037 | Shares Floating 24308835 |
Shares Outstanding 35850037 | Shares Floating 24308835 | ||
Percent Insiders 3.63 | Percent Institutions 68 |
Upturn AI SWOT
BioAge Labs, Inc
Company Overview
History and Background
BioAge Labs, Inc. is a privately held clinical-stage biotechnology company focused on developing therapies to treat aging-related diseases. Founded in 2015, the company utilizes a data-driven approach, analyzing human aging data to identify promising drug targets. Key milestones include securing funding rounds, initiating clinical trials for its lead compounds, and publishing research validating its therapeutic targets.
Core Business Areas
- Drug Discovery and Development: Identifies and develops therapies that target the molecular pathways of aging to treat aging-related diseases. They are currently working on medications to treat age-related diseases such as immunosenescence, muscle aging, and cognitive decline.
- Data Analytics and Research: Uses proprietary data analytics platform to analyze human aging data to identify drug targets and predict therapeutic outcomes.
Leadership and Structure
BioAge Labs is led by Kristen Fortney (CEO) and a team of experienced scientists and drug developers. The company has a board of directors and operates with functional departments including research, development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- BGE-175 (ApoE4 mimetic): A small molecule ApoE4 mimetic targeting muscle aging and immunosenescence. Currently in clinical trials. No specific market share data available as product is in development. Competitors include companies working on sarcopenia and immunosenescence therapies, such as Juvenescence and Alkahest (acquired by Grifols).
- BGE-117 (Rejuvantu00ae): Rejuvant is an amino acid dietary supplement designed to promote healthy aging. Available directly to consumers. No specific market share data available. Competitors include Elysium Health, Life Extension, and other nutraceutical companies focused on longevity.
Market Dynamics
Industry Overview
The biotechnology industry is experiencing rapid growth, particularly in the area of aging-related diseases. Driven by an aging population and increasing awareness of preventative health, companies focused on longevity are attracting significant investment.
Positioning
BioAge Labs is positioned as a data-driven drug discovery company focused on targeting fundamental aging pathways. Its competitive advantage lies in its proprietary data analytics platform and focus on human aging data.
Total Addressable Market (TAM)
The global market for aging-related disease therapeutics is estimated to be worth hundreds of billions of dollars. BioAge Labs is positioned to capture a significant share of this market by developing novel therapies and establishing strategic partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary data analytics platform
- Experienced leadership team
- Focus on validated aging pathways
- Clinical-stage pipeline
Weaknesses
- Limited financial resources as a private company
- Dependence on clinical trial outcomes
- High regulatory hurdles
- Small team size compared to large competitors
Opportunities
- Strategic partnerships with pharmaceutical companies
- Expansion of pipeline through new target identification
- Positive clinical trial results
- Increasing investor interest in longevity therapeutics
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from larger pharmaceutical companies
- Changes in the regulatory landscape
Competitors and Market Share
Key Competitors
- Elysium Health (Privately Held)
- Juvenescence (Privately Held)
- Alkahest (Privately Held, Acquired by Grifols - GRFS)
Competitive Landscape
BioAge Labs is in a competitive landscape with both established pharmaceutical companies and emerging biotech firms focused on longevity. Its advantages include its data-driven approach and focus on human aging data. Disadvantages include limited financial resources compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: BioAge Labs has experienced significant growth in terms of funding, pipeline development, and team expansion since its founding in 2015.
Future Projections: Future growth is dependent on clinical trial outcomes, regulatory approvals, and securing additional funding. Analyst estimates are not available due to the company being private.
Recent Initiatives: Recent initiatives include progressing its lead compounds through clinical trials, expanding its data analytics platform, and forging partnerships with research institutions.
Summary
BioAge Labs is a promising clinical-stage biotechnology company focused on developing therapies for aging-related diseases. Its data-driven approach and experienced leadership team are significant strengths. The company faces challenges including clinical trial risks, regulatory hurdles, and competition from larger players. Successful clinical trials and strategic partnerships will be critical for its future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Press releases
- Venture capital databases
- Industry reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. The biotechnology industry is inherently risky, and investment decisions should be made with careful consideration of all factors.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioAge Labs, Inc
Exchange NASDAQ | Headquaters Richmond, CA, United States | ||
IPO Launch date 2024-09-26 | Co-Founder, CEO, President, Treasurer, Secretary & Director Dr. Kristen Fortney Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 62 | Website https://bioagelabs.com |
Full time employees 62 | Website https://bioagelabs.com | ||
BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It develops BGE-102, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.